Tidemark LLC Sells 332 Shares of Bristol-Myers Squibb (NYSE:BMY)

Tidemark LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 13.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,063 shares of the biopharmaceutical company’s stock after selling 332 shares during the period. Tidemark LLC’s holdings in Bristol-Myers Squibb were worth $117,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of BMY. one8zero8 LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $2,001,000. Globeflex Capital L P acquired a new stake in shares of Bristol-Myers Squibb during the fourth quarter worth about $34,062,000. Natixis Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 52.5% during the 4th quarter. Natixis Advisors LLC now owns 680,841 shares of the biopharmaceutical company’s stock valued at $38,508,000 after purchasing an additional 234,477 shares in the last quarter. Frank Rimerman Advisors LLC grew its position in shares of Bristol-Myers Squibb by 4.2% in the 4th quarter. Frank Rimerman Advisors LLC now owns 41,378 shares of the biopharmaceutical company’s stock valued at $2,340,000 after purchasing an additional 1,667 shares during the period. Finally, Van Strum & Towne Inc. increased its stake in Bristol-Myers Squibb by 2.7% during the 4th quarter. Van Strum & Towne Inc. now owns 17,092 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 450 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Down 2.1 %

Bristol-Myers Squibb stock opened at $59.01 on Friday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33. The firm has a market capitalization of $119.75 billion, a PE ratio of -13.35, a P/E/G ratio of 2.07 and a beta of 0.43. The company’s 50-day moving average is $57.81 and its 200-day moving average is $55.57. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. Sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 4.20%. Bristol-Myers Squibb’s dividend payout ratio is currently -56.11%.

Insider Activity

In other news, EVP Samit Hirawat purchased 1,823 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the acquisition, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This trade represents a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on BMY shares. Citigroup lifted their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Bank of America reaffirmed a “neutral” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Friday, February 7th. Cantor Fitzgerald upped their price objective on Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Finally, Truist Financial lifted their target price on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.